Show Summary Details
Page of

Vaccines 

Vaccines
Chapter:
Vaccines
Author(s):

Max V. Kuenstling

, Eric J. Benner

, and R. Lee Mosley

DOI:
10.1093/med/9780195399349.003.0010
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 May 2019

The ultimate goal of vaccination is to deliver effective immunity that, under conditions of disease exposure, either prevents infection or allows rapid clearance of infected cells. However, developing an effective vaccine for HIV-1 is fraught with difficulties. A major challenge is the speed with which HIV-1 incorporates its genomic information into host DNA in the form of a relatively inaccessible latent provirus. Other challenges include the (to date) inability of vaccines to elicit adequate neutralizing antibodies in humans; difficulties in finding adequate small-animal models for vaccine research; and the threat that an otherwise-effective vaccine would, by stimulating an immune response in the brain, itself exacerbate the inflammatory activation that appears to play a central role in the neuropathogenesis of HIV-1 infection. This chapter aims to provide an understanding of the challenges that have impeded the development of a successful HIV vaccine, and to describe some potentially effective strategies that may ultimately provide at least some clinically important level of vaccine protection. As part of the presentation, the results of clinical vaccine trials are discussed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.